You can buy or sell GlycoMimetics and other stocks, options, ETFs, and crypto commission-free!
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. Read More The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD. The listed name for GLYC is GlycoMimetics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, Pre-Market